Total
0
Shares
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson - The Market Herald
CEO, Wayne Paterson
Source: Anteris Technologies
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Anteris Technology (AVR) has entered a $1.2 million lending facility in advance of an upcoming research and development tax incentive
  • The short-term facility is an immediate equivalent to the refund it expects from the Australia government in 2021
  • The government incentive provides a refundable tax offset for eligible research and development activities by Australian businesses
  • Most notably, funding is hoped to speed up the development of its DurAVRTM, Anteris’ 3D single-piece Aortic Valve which has shown promising early research findings
  • The company is currently in a trading halt as per an announcement on December 23
  • Anteris shares last traded at $3.75 each

Anteris Technology has entered a $1,220,000 million lending facility ahead of an upcoming research and development tax incentive.

The short-term facility is an immediate equivalent to an Australian government tax incentive refund Anteris expected in 2021.

The government incentive provides a refundable tax offset for eligible research and development activities by Australian businesses with an aggregated turnover of less than $20 million.

The advance is primarily secured against the research and development refund expected in 2021 for the 10 months ended October 31, 2021.

Mitchell Asset Management is providing the loan facility.

A company statement says the facility confirms its significant and ongoing commitment to invest in research and develop its ADAPT heart tissue technologies.

Funding is hoped to speed up the development of its DurAVRTM, Anteris’ 3D single-piece Aortic Valve, which has shown promising early research findings.

The company is currently in a trading halt as per an announcement on December 23, the announcement does not lift the current trading halt.

Anteris shares last traded at $3.75 each.

AVR by the numbers
More From The Market Herald
Incannex Healthcare (ASX:IHL) - Chief Medical Officer, Dr Sud Agarwal (centre) - The Market Herald

" Incannex Healthcare (ASX:IHL) declares outstanding half-year revenue growth

Incannex Healthcare (IHL) has reported a revenue growth of 11,859 per cent to $1.23 million for the six months to December 31, 2020.
Imagion Biosystems (ASX:IBX) - CEO & Executive Chairman, Bob Proulx - The Market Herald

" Imagion Biosystems (ASX:IBX) increases full-year revenue as it advances cancer detection tech

Imagion Biosystems (IBX) has revealed stronger full-year revenue for 2020 as it takes on the first-in-human trial of its MagSense cancer detection tech.
Zoono (ASX:ZNO) - Managing Director & CEO, Paul Hyslop - The Market Herald

" Zoono Group’s (ASX:ZNO) revenue soars 741pc to A$13.4M

For the six months ending December 31, 2020, Zoono Group (ZNO) reported a 362 per cent increase in net profit after tax to
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley - The Market Herald

" Starpharma (ASX:SPL) deepens loss in latest interim report

Biopharma Starpharma (SPL) has released its interim report and financial results for the 2021 financial year.